Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2021-04-29 Capital/Financing Update
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between NKMAX and Green Cross LabCell. It details the contract value, counterparty, and terms. Since this is a specific corporate event disclosure that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2021-04-29 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (NKMAX) regarding a 'Single Sales/Supply Contract' amendment. It details a correction to a previously filed contract disclosure, specifically updating the contract end date. Since this is a specific regulatory disclosure regarding a commercial contract and does not fit into categories like M&A, Earnings, or Dividends, it falls under the general regulatory filing category.
2021-04-29 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company NKMAX, dated 2021-03-29. It details the outcomes of various agenda items, including the approval of financial statements, election of directors and auditors, and remuneration limits. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official record of shareholder votes and meeting resolutions.
2021-03-29 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMAX) regarding a correction to a previously filed financial disclosure ('매출액 또는 손익구조 30%이상 변동'). It details specific adjustments to financial figures (revenue, operating profit, net income) following an external audit. Since this is a formal regulatory correction filing (DART system style) and not a full annual report or a simple announcement of a report, it falls under the 'Regulatory Filings' category. FY 2020
2021-03-19 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) for a 'Notice of Annual General Meeting' (주주총회소집공고). It details specific corrections made to the original notice, including updates to electronic voting procedures and financial statements (재무제표). Since this is a formal document related to the logistics and agenda of an upcoming Annual General Meeting, it falls under the category of Proxy Solicitation & Information Statement, which covers materials sent to shareholders for meeting purposes.
2021-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by NKMAX. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and key financial metrics (assets, liabilities, profit/loss). While it provides financial data, it is a regulatory filing specifically announcing the submission of the audit report to the exchange, which is a standard requirement for public companies. Given the structure and content, it falls under the category of Audit Report / Information. FY 2020
2021-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.